Total neurological recovery after surgical decompression and treatment with denosumab of large unresectable spinal giant cell tumour expanding to mediastinum.
Chirathit AnusitviwatMonchai RuangchainikomEkkapoj KorwutthikulrangsriWerasak SutipornpalangkulPublished in: BMJ case reports (2022)
There is a controversy over the medical treatment of unresectable spinal giant cell tumour (GCT) regarding dosing and duration. We studied a spinal GCT case that had expanded to the thoracic spinal canal and mediastinum and was successfully treated by surgical decompression and denosumab. A woman in her 30s presented with weakness in both the lower extremities. MRI revealed a large tumour in the posterior mediastinum expanding from the thoracic vertebrae (T3-6), which compressed the spinal cord. The patient underwent urgent spinal decompression with instrumentation and her tissue was sent for a pathology study. Histologically and immunohistochemistry confirmed the diagnosis of GCT. Since it was an unresectable tumour, this patient was treated with denosumab. Her neurological problem resolved after 6 months of treatment. After 4 years of follow-up, the patient displayed no further progression and no side effects from long-term denosumab usage.
Keyphrases
- giant cell
- spinal cord
- case report
- bone mineral density
- neuropathic pain
- spinal cord injury
- healthcare
- magnetic resonance imaging
- locally advanced
- computed tomography
- squamous cell carcinoma
- combination therapy
- magnetic resonance
- radiation therapy
- replacement therapy
- body composition
- brain injury
- postmenopausal women
- single cell
- subarachnoid hemorrhage
- newly diagnosed